News
New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinibREDWOOD CITY, Calif., ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results